ViRexx Medical Corp.

ViRexx Medical Corp.

January 30, 2006 12:07 ET

ViRexx Invited to Attend the Capitol Hill BioDefense Showcase

EDMONTON, ALBERTA--(CCNMatthews - Jan. 30, 2006) - ViRexx Medical Corp. (TSX:VIR) (AMEX:REX), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, today announced that it will attend the Capitol Hill BioDefense Advisory Showcase & Roundtable on Tuesday, January 31, 2006. ViRexx will focus on the capabilities of its Chimigen™ platform which can be used both as a therapeutic product and a prophylactic vaccine to treat chronic viral infections.

"Our Chimigen™ technology could have biodefense applications. The flexibility of the Chimigen™ platform is the ability to insert different relevant antigens to the antibody fragment," said Dr. Lorne Tyrrell, CEO of ViRexx Medical Corp. "Our Chimigen™ technology has demonstrated a broad immune response that includes both cellular and humoral responses in preclinical studies."

The Chimigen™ platform is one of three technologies under development at ViRexx. The Company expects to initiate a Phase I safety study in Canada shortly for its first Chimgen™ related product HepaVaxx B, a therapeutic vaccine for chronic carriers of hepatitis B.

The Showcase and Roundtable is be hosted by Congressman John Linder, Chairman of the House subcommittee with jurisdiction over biodefense.

About ViRexx Medical Corp.

ViRexx is an Edmonton, Alberta based biotechnology company focused on the development of novel therapeutic products for the treatment of certain cancers and specified chronic viral infections. ViRexx's most advanced programs include drug candidates for the treatment of ovarian cancer, chronic hepatitis B and C and solid tumors.

ViRexx's lead product candidate, OvaRex® MAb, a therapy for the treatment of late-stage ovarian cancer, is currently the subject of two Phase III clinical trials being funded by ViRexx's licensing partner Unither Pharmaceuticals, Inc., a subsidiary of United Therapeutics Corporation. For additional information about ViRexx, please see

About the Capitol Hill Biodefense and Advisory Showcase and Roundtable

The development of effective biodefense capabilities has become crucial, with the increased possibilities of a global flu pandemic or terrorist attack, and is a top priority on the U.S. and global agendas. This Capitol Hill forum discusses new programs, strategies, and funding with key business and government leaders, while showcasing biodefense solutions.

This news release contains certain forward-looking statements that reflect the current views and/or expectations of the Company with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

The TSX has not approved or disapproved of the information contained herein

Contact Information

  • ViRexx Medical Corp.
    Lorne Tyrrell
    Chief Executive Officer
    (780) 433-4411
    (780) 436-0068 (FAX)
    ViRexx Medical Corp.
    Marc Canton
    President & Chief Operating Officer
    (780) 433-4411
    (780) 436-0068 (FAX)